Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
86.28
+0.50 (0.58%)
At close: Nov 7, 2025, 4:00 PM EST
86.30
+0.02 (0.03%)
After-hours: Nov 7, 2025, 7:57 PM EST
Merck & Co. Revenue
Merck & Co. had revenue of $17.28B in the quarter ending September 30, 2025, with 3.72% growth. This brings the company's revenue in the last twelve months to $64.24B, up 1.68% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$64.24B
Revenue Growth
+1.68%
P/S Ratio
3.38
Revenue / Employee
$856,467
Employees
75,000
Market Cap
214.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
MRK News
- 20 hours ago - Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial - Business Wire
- 5 days ago - Merck and Blackstone enter research agreement to develop cancer therapy for $700 million - Reuters
- 5 days ago - Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) - Business Wire
- 5 days ago - Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody - Business Wire
- 6 days ago - Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S. - Business Wire
- 7 days ago - Top 10 High-Yield Dividend Stocks For November 2025 - Seeking Alpha
- 8 days ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Nov. 2025) - Seeking Alpha
- 9 days ago - Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript - Seeking Alpha